purity testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
=== Nicht-Injektionsbedingte Sarkome === Bei nicht-Injektionsbedingten Sarkomen (feline non-injection-site sarcoma, FNISS) ist eine vorherige Injektion unwahrscheinlich oder zumindest nicht ermittelbar. Sie treten an allen Körperstellen auf. Man nimmt an, dass sie durch spontane genetische Veränderungen entstehen. Auch die FNISS wachsen infiltrativ, die Pleomorphie ist pathohistologisch aber weniger ausgeprägt und Entzündungsinfiltrate und Nekrosen sind seltener. Neben der Lokalisation an Rumpf und Gliedmaßen kommen Fibrosarkome auch in der Maulhöhle vor. Der Entstehungsmechanismus ist dort ebenfalls unklar, eine Beteiligung von Viren kann aber ausgeschlossen werden.
=== Virusbedingte Sarkome === Weichteilsarkome können auch durch das zur den Retroviren gehörende feline Sarkomvirus (FeSV) ausgelöst werden. Typischerweise treten die virusbedingten Fibrosarkome an mehreren Körperstellen gleichzeitig auf und es sind vor allem junge und jugendliche Katzen betroffen. FeSV-induzierte Sarkome sind meist wenig differenziert und neigen früh zu Metastasen in die Lunge und andere Organe. Sie wachsen noch schneller und invasiver als die anderen Fbrosarkome. Sie können sich aber auch als große Solitärtumoren darstellen, die sich spontan wieder zurückbilden.
== Häufigkeit == Sarkome sind bei Katzen die häufigsten Tumoren mit einem Anteil von 42 %. Das Fibrosarkom ist bei Katzen mit 15 bis 17 % der vierthäufigste Hauttumor und stellt mit etwa 40 % aller Fälle die zweithäufigste bösartige Tumorform der Haut bei Hauskatzen dar. Das erste als Impfreaktion entstandene Fibrosarkom bei Katzen wurde 1991 in den Vereinigten Staaten beschrieben, dies fällt zeitlich mit dem verstärkten Einsatz von Tollwut- und FeLV-Impfstoffen in den Vereinigten Staaten zusammen. Eine Übersichtsarbeit und Metaanalyse von 2026 ermittelte eine Häufigkeit von 8,8 Fälle auf 100.000 Impfungen. 2011 wurde erstmals ein solcher Tumor an der Implantationsstelle eines Mikrochips zur Tierkennzeichnung beobachtet. Es gibt keine Rasse- oder Geschlechtsdisposition. Daten aus der Schweiz und eines großen Diagnostiklabors in Deutschland zeigen in den letzten Jahren eine Abnahme der Häufigkeit der Erkrankung, was mit dem zunehmenden Einsatz von Impfstoffen ohne Adjuvanzien zusammenhängen könnte. Die Häufigkeit von FeSV-bedingten Sarkomen hat mit dem Rückgang der Häufigkeit von das Immunsystem schädigenden FeLV-Infektionen in den letzten Jahren ebenfalls abgenommen. Fibrosarkome der Maulhöhle sind bei Katzen wesentlich seltener als Plattenepithelkarzinome und auch deutlich seltener als beispielsweise beim Hund, sie machen bei Katzen etwa 6 bis 17 % der oralen Tumoren aus. Betroffene Tiere sind im Mittel 10 Jahre alt. Beim Menschen sind Weichteilsarkome selten, sie machen nur etwa 1 % der bösartigen Tumorerkrankungen aus.
Das Fibrosarkom speziell hat dabei eine Inzidenz von 0,2 von 100,000 Fällen. Diese Seltenheit macht es schwer, geeignete Behandlungsstrategien für den Menschen zu entwickeln, weshalb Katzen hier als Modelltier dienen könnten. Während beim Menschen mittlerweile über 100 Arten von Weichteilsarkomen unterschieden werden, untergliedert man diese bei Katzen nach wie vor vor allem nach dem histologischen Bild. Neuere genetische Untersuchungen zeigten bei Katzen drei Untertypen von Fibrosarkomen.
Sources: de.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.